TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(FY)Jun 30, 2024 | (Q6)Dec 31, 2023 | (FY)Jun 30, 2023 | (Q6)Dec 31, 2022 | (FY)Jun 30, 2022 | (Q6)Dec 31, 2021 | (FY)Jun 30, 2021 | (Q6)Dec 31, 2020 | (FY)Jun 30, 2020 | (Q6)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | -34.49%-213.02M | ---- | -22.07%-158.4M | ---- | -1,403.93%-129.76M | ---- | 90.66%-8.63M | ---- | 58.39%-92.41M | ---- |
Profit adjustment | ||||||||||
Interest (income) - adjustment | 38.68%-3.43M | ---- | -79.17%-5.59M | ---- | 23.15%-3.12M | ---- | 45.30%-4.06M | ---- | -49.86%-7.42M | ---- |
Investment loss (gain) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---14.24M | ---- |
Attributable subsidiary (profit) loss | --54.13M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Impairment and provisions: | -43.29%1.31M | ---- | 1.14%2.3M | ---- | 336.21%2.28M | ---- | 208.07%522K | ---- | -105.52%-483K | ---- |
-Impairmen of inventory (reversal) | -50.11%1.31M | ---- | 86.07%2.62M | ---- | 127.30%1.41M | ---- | 228.16%619K | ---- | -268.88%-483K | ---- |
-Impairment of trade receivables (reversal) | ---- | ---- | -136.21%-315K | ---- | --870K | ---- | ---- | ---- | ---- | ---- |
-Other impairments and provisions | ---- | ---- | ---- | ---- | ---- | ---- | ---97K | ---- | ---- | ---- |
Revaluation surplus: | -288.58%-413K | ---- | 109.56%219K | ---- | 74.47%-2.29M | ---- | 54.42%-8.97M | ---- | -5,011.95%-19.68M | ---- |
-Derivative financial instruments fair value (increase) | -288.58%-413K | ---- | 109.56%219K | ---- | 74.47%-2.29M | ---- | 54.42%-8.97M | ---- | -5,011.95%-19.68M | ---- |
Asset sale loss (gain): | -25,820.93%-11.06M | ---- | -96.09%43K | ---- | -40.24%1.1M | ---- | 6.42%1.84M | ---- | 104.50%1.73M | ---- |
-Loss (gain) from sale of subsidiary company | ---11.14M | ---- | ---- | ---- | 100.18%3K | ---- | ---1.69M | ---- | ---- | ---- |
-Loss (gain) on sale of property, machinery and equipment | 86.05%80K | ---- | -96.08%43K | ---- | -68.96%1.1M | ---- | 104.34%3.53M | ---- | 104.50%1.73M | ---- |
Depreciation and amortization: | 45.10%37.92M | ---- | 5.13%26.13M | ---- | -31.76%24.86M | ---- | -29.59%36.43M | ---- | 114.99%51.73M | ---- |
-Amortization of intangible assets | --5.09M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Financial expense | 11.50%88.12M | ---- | 87.06%79.03M | ---- | -9.36%42.25M | ---- | -42.92%46.61M | ---- | 2.92%81.66M | ---- |
Unrealized exchange loss (gain) | -53.69%5.27M | ---- | 36.99%11.39M | ---- | 123.34%8.31M | ---- | -276.10%-35.61M | ---- | 91.69%20.22M | ---- |
Special items | 196.59%85K | ---- | -100.93%-88K | ---- | 558.88%9.43M | ---- | 82.62%-2.06M | ---- | -113.76%-11.82M | ---- |
Operating profit before the change of operating capital | 8.60%-41.09M | ---- | 4.23%-44.96M | ---- | -280.05%-46.94M | ---- | 180.92%26.07M | ---- | 151.77%9.28M | ---- |
Change of operating capital | ||||||||||
Inventory (increase) decrease | -774.05%-210.32M | ---- | -45.06%31.2M | ---- | 1,644.20%56.79M | ---- | -98.37%3.26M | ---- | 108.72%200.31M | ---- |
Accounts receivable (increase)decrease | -322.37%-26.79M | ---- | -662.23%-6.34M | ---- | -37.92%1.13M | ---- | -97.14%1.82M | ---- | 174.21%63.55M | ---- |
Accounts payable increase (decrease) | 3.60%20.94M | ---- | 195.56%20.21M | ---- | -122.94%-21.15M | ---- | 81.77%-9.49M | ---- | 32.96%-52.06M | ---- |
Special items for working capital changes | -548.10%-4.02M | ---- | 142.50%896K | ---- | -115.11%-2.11M | ---- | 280.14%13.95M | ---- | 88.07%-7.75M | ---- |
Cash from business operations | -25,892.10%-261.27M | ---- | 108.25%1.01M | ---- | -134.50%-12.29M | ---- | -83.31%35.61M | ---- | 616.07%213.33M | ---- |
Other taxs | 373.95%1.1M | ---- | -108.29%-403K | ---- | 150.13%4.86M | ---- | 50.65%-9.7M | ---- | -168.99%-19.66M | ---- |
Special items of business | ---- | 137.07%1.63M | ---- | 80.79%-4.4M | ---- | -128.85%-22.92M | ---- | -47.81%79.45M | ---- | 218.53%152.24M |
Net cash from operations | -42,750.82%-260.17M | 137.07%1.63M | 108.22%610K | 80.79%-4.4M | -128.65%-7.42M | -128.85%-22.92M | -86.62%25.91M | -47.81%79.45M | 498.14%193.68M | 218.53%152.24M |
Cash flow from investment activities | ||||||||||
Interest received - investment | -0.55%5.04M | 80.40%4.12M | 83.98%5.07M | 44.46%2.28M | -33.47%2.75M | -48.77%1.58M | -41.81%4.14M | -29.76%3.08M | 41.18%7.11M | 147.91%4.39M |
Decrease in deposits (increase) | 1,298.20%862.85M | -0.61%-21.66M | -112.86%-72.01M | -1,231.42%-21.53M | -444.13%-33.83M | -115.46%-1.62M | -94.22%9.83M | -86.34%10.46M | 183.96%170.07M | 143.27%76.59M |
Sale of fixed assets | ---- | 0.00%1K | -96.12%5K | -95.45%1K | -88.67%129K | -91.13%22K | -81.76%1.14M | -95.82%248K | 1,668.56%6.24M | 1,878.67%5.94M |
Purchase of fixed assets | -154.29%-26.22M | 50.47%-3.56M | -6.18%-10.31M | -9.11%-7.19M | -25.34%-9.71M | -137.42%-6.59M | 9.83%-7.75M | 40.00%-2.77M | 73.80%-8.59M | 72.66%-4.62M |
Sale of subsidiaries | ---3.45M | ---- | ---- | ---- | -100.19%-7K | ---- | --3.64M | ---- | ---- | ---- |
Recovery of cash from investments | ---- | ---- | ---- | ---- | ---- | ---- | --2.49M | ---- | ---- | ---- |
Net cash from investment operations | 1,185.06%838.22M | 20.16%-21.1M | -89.97%-77.25M | -300.38%-26.43M | -401.42%-40.67M | -159.93%-6.6M | -92.28%13.49M | -86.61%11.02M | 178.65%174.83M | 144.68%82.29M |
Net cash before financing | 854.23%578.05M | 36.85%-19.47M | -59.38%-76.64M | -4.44%-30.84M | -222.05%-48.09M | -132.64%-29.52M | -89.31%39.4M | -61.43%90.46M | 236.01%368.51M | 175.02%234.53M |
Cash flow from financing activities | ||||||||||
New borrowing | 604.49%1.31B | -26.64%53.53M | 56.56%186.3M | --72.97M | 115.78%119M | ---- | -30.19%55.15M | -66.79%27M | -92.96%79M | -92.45%81.3M |
Refund | -5,814.58%-1.84B | 66.16%-10M | 64.03%-31.12M | 34.34%-29.55M | -48.12%-86.5M | 22.95%-45M | 87.97%-58.4M | 70.82%-58.4M | 35.53%-485.57M | 73.42%-200.16M |
Issuing shares | ---- | ---- | ---- | ---- | --142M | --142M | ---- | ---- | 133.49%121.95M | ---- |
Interest paid - financing | 5.71%-67.09M | -95.44%-55.99M | -69.19%-71.15M | -18.77%-28.65M | -19.00%-42.05M | -18.78%-24.12M | 51.18%-35.34M | 46.73%-20.31M | 0.10%-72.38M | -17.99%-38.12M |
Issuance expenses and redemption of securities expenses | ---- | ---- | ---- | ---- | ---79.95M | ---79.95M | ---- | ---- | ---- | ---- |
Net cash from financing operations | -1,025.31%-618.49M | -435.07%-22.45M | 73.92%66.84M | 146.66%6.7M | 165.64%38.43M | 77.33%-14.36M | 84.76%-58.55M | 63.56%-63.33M | -210.28%-384.3M | -154.69%-173.8M |
Effect of rate | 131.40%1.12M | 165.84%2.14M | -87.60%-3.57M | -397.26%-3.26M | -142.28%-1.9M | 104.21%1.1M | 173.15%4.5M | -496.72%-26.01M | -249.21%-6.15M | -153.37%-4.36M |
Net Cash | -312.57%-40.43M | -73.71%-41.93M | -1.49%-9.8M | 45.00%-24.14M | 49.58%-9.66M | -261.74%-43.88M | -21.28%-19.15M | -55.32%27.13M | -120.37%-15.79M | 1,073.88%60.73M |
Begining period cash | -15.80%71.23M | -15.80%71.23M | -12.02%84.6M | -12.02%84.6M | -13.22%96.16M | -13.22%96.16M | -16.53%110.81M | -16.53%110.81M | 132.95%132.76M | 132.95%132.76M |
Cash at the end | -55.19%31.92M | -45.03%31.45M | -15.80%71.23M | 7.20%57.21M | -12.02%84.6M | -52.32%53.37M | -13.22%96.16M | -40.81%111.94M | -16.53%110.81M | 212.90%189.12M |
Cash balance analysis | ||||||||||
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Auditor | Guofu Haohua (Hong Kong) Certified Public Accountants Limited | -- | Guofu Haohua (Hong Kong) Certified Public Accountants Limited | -- | Guofu Haohua (Hong Kong) Certified Public Accountants Limited | -- | Guofu Haohua (Hong Kong) Certified Public Accountants Limited | -- | Guofu Haohua (Hong Kong) Certified Public Accountants Limited | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.